After following these patients for a median of four years, they found that patients treated with anti-TNF-alpha therapy experienced an aortic de-stiffening (8.5 m/s at baseline vs. 7.9 m/s at follow-up, p=0.02) when compared to IBD patients treated with another therapy like salicylates [9]. The gene discussed is TNF; the disease is inflammatory bowel disease.